VRNA Company Profile and Key Details

Q: Who are the executives of VRNA?

Ms. Ostra JewellSenior Vice President of HRDr. Kathleen A. RickardChief Medical OfficerDr. David S. ZaccardelliPres, Chief Executive Officer & Executive DirectorDr. Tara Rheault M.P.H., Ph.D.Senior Vice President of R&DDr. Peter SpargoSenior Vice President of Chemistry Manufacturing & ControlsMs. Nina ChurchExecutive Director of Global Clinical Devel.Ms. Victoria StewartDirector of CommunicationsMr. Matthew CasbonVice President of Sales, Marketing & TrainingMr. Mark W. HahnChief Financial OfficerMs. Claire Louise Poll L.C.S.W., B.A., B Juris, LLB, ASIAGen. Counsel

NASDAQ : VRNA

Verona Pharma

$106.91

0.12+0.11%

At Close 4:00 PM

Not Actively Trading

58.58

BESG ScoreESG Rating

Profile Key Stats Analyst Ratings Ownership Ratios Financials Dividend & splits Sentiment Forecast

Price Chart

Stock Price Today

Verona Pharma plc (VRNA) stock surged +0.11%, trading at $106.91 on NASDAQ, up from the previous close of $106.79. The stock opened at $106.91, fluctuating between $106.91 and $106.91 in the recent session.

Stock Snapshot

106.79

Prev. Close

72.68B

Market Cap

106.91

Day Low

-102.79807692307692

P/E Ratio

-1.04

EPS (TTM)

-0.63

Cash Flow per Share

106.91

Open

679.83M

Number of Shares

106.91

Day High

83.08%

Free Float in %

3.11

Book Value

1.87M

Volume

Relevant Articles

SEC Fillings

Current Report (8-k)

Filing Date	Accepted Date

Annual Report (10-k)

Filing Date	Accepted Date

Stock Price History Chart

Date	Open	High	Low	Close	Volume
Oct 06, 2025	106.85	106.93	106.81	106.91	1.87M
Oct 03, 2025	106.84	106.85	106.79	106.79	1.68M
Oct 02, 2025	106.85	106.86	106.76	106.82	981.84K
Oct 01, 2025	106.70	106.85	106.67	106.82	1.06M
Sep 30, 2025	106.65	106.75	106.61	106.71	1.8M
Sep 29, 2025	106.75	106.75	106.61	106.61	1.14M
Sep 26, 2025	106.71	106.73	106.66	106.69	1.27M
Sep 25, 2025	106.73	106.75	106.61	106.69	3.16M
Sep 24, 2025	106.25	106.41	106.25	106.39	1.26M
Sep 23, 2025	106.21	106.29	106.15	106.25	1.29M
Sep 22, 2025	106.25	106.29	106.13	106.25	1.24M
Sep 19, 2025	106.28	106.30	105.85	106.02	1.82M
Sep 18, 2025	106.28	106.34	106.22	106.26	1.52M
Sep 17, 2025	106.30	106.38	106.18	106.29	3.19M
Sep 16, 2025	106.36	106.43	106.26	106.27	1.46M
Sep 15, 2025	106.43	106.45	106.30	106.37	1.22M
Sep 12, 2025	106.30	106.45	106.30	106.43	918.69K
Sep 11, 2025	106.33	106.40	106.30	106.40	1M
Sep 10, 2025	106.42	106.42	106.25	106.37	910.47K
Sep 09, 2025	106.27	106.38	106.23	106.30	932.8K

Contact Details

London, SE1 2RE

United Kingdom

https://www.veronapharma.com 442 032 834200

About Company

Verona Pharma plc is a biopharmaceutical company currently in its clinical development phase, focusing on the research, development, and eventual market launch of new therapies for respiratory illnesses where current treatments are inadequate. Its primary experimental medication is ensifentrine, an inhaled compound designed to simultaneously block both phosphodiesterase (PDE) 3 and PDE4 enzymes. This unique mechanism allows it to function both as a bronchodilator, helping to open the airways, and as an anti-inflammatory agent within a single drug. Ensifentrine is presently undergoing advanced (Phase 3) clinical trials to evaluate its effectiveness in treating chronic obstructive pulmonary disease (COPD), asthma, and cystic fibrosis. To provide versatile administration options, the company is developing ensifentrine in three distinct formulations: a nebulizer solution, a dry powder inhaler (DPI), and a pressurized metered-dose inhaler (pMDI). Verona Pharma plc was established in 2005 and conducts its operations from its headquarters in London, United Kingdom.

Stock Peers

ARGX

26.03+2.97%

argenx SE$903.75 REGN

2.56+0.42%

Regeneron Pharmaceuticals, Inc.$612.50 UTHR

1.70998+0.32%

United Therapeutics Corporation$538.30 MDGL

7.13+1.41%

Madrigal Pharmaceuticals, Inc.$512.88 VRTX

15.16+3.36%

Vertex Pharmaceuticals Incorporated$466.79 KRYS

-4.63-1.33%

Krystal Biotech, Inc.$343.43 KRTX

0.09+0.03%

Karuna Therapeutics, Inc.$329.83 PRAX

21.08+7.47%

Praxis Precision Medicines, Inc.$303.39 ALNY

8.32+2.99%

Alnylam Pharmaceuticals, Inc.$286.41 LGND

-12.71-4.62%

Ligand Pharmaceuticals Incorporated$262.17

Company Overview

Verona Pharma plc (NASDAQ:VRNA) closed at $106.91 USD, gaining $0.12 (0.11%) from the previous close of $106.79. The stock is currently trading near its 52-week high $31.09 and $106.93. With a market capitalization of about $72.68 billion, Verona Pharma plc is classified as a large-cap and shows lower-than-market volatility (beta ~0.05). Key stats such as the average daily volume over the past year has been around 3.56 million shares, volume is running light vs its 52-week average. Headquartered in London, None, Verona Pharma plc operates in the Healthcare sector and the Biotechnology industry. Led by CEO David S. Zaccardelli, the company employs approximately 209 people and listed since April 28, 2017. Verona Pharma plc is a biopharmaceutical company currently in its clinical development phase, focusing on the research, development, and eventual market launch of new therapies for respiratory illnesses where current treatments are inadequate.

Technical Performance

Short-term trend indicators are bearishly aligned (SMA20 0.4%, SMA50 0.92%, SMA200 35.92%). The stock’s 14-day RSI is 72.54 (overbought), while the ATR of 0.23 points to tighter daily ranges. The stock remains hovering near 52-week lows, trading -0.02% below its high and over 243.87% above its low.

Valuation Metrics

Verona Pharma plc trades at a P/E ratio of -295.69, slightly below the S&P 500 average, with a price-to-sales ratio of 444.67 and a price-to-book ratio of 32.9 reflecting a rich premium to book value. The P/FCF stands at -7008.07, also below market averages. Compared to sector medians, Verona Pharma plc P/S is trading rich, and the P/B is far higher than peers, underscoring the brand and earnings power premium investors assign to the stock.

Dividend & Fair Value

Verona Pharma plc last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $35.19. This means the shares are trading above this model’s fair value.

Earnings & Analyst Outlook

Verona Pharma plc generated EPS of -$1.03 over the past year. Five-year average earnings growth is 7.21%. The latest quarter delivered EPS of -$0.56. The next quarter is forecast at $0.01. Next year's EPS is expected at -$27.72. Analyst sentiment is neutral. Analyst rating data shows there are 3 Strong Buy ratings, 0 Buy ratings, 4 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $170.00 to $100.00. The high target offers 59.01% upside. The low target suggests -6.46% downside. The mean target is $122.57. This offers 14.65% upside. Verona Pharma plc earnings surprise history is frequent misses against expectations. The quarter that ended November 03, 2025, missed forecasts by -450.0%. The prior quarter beat by -1400.0%. Over the last six quarters, Apple has recorded several small beats. These include -60.48% in August 08, 2024.

Shareholding & Insider Activity

Verona Pharma plc has 84.98 million shares outstanding. The public float is 564.82 million shares, elevated short interest at 2.42% of float. This equals 2.01 million shares. The short ratio is 1.34 days. Institutional investors hold 99.9% of the float. Insiders own 4.89%. Blavatnik Len holds 55.91 million shares, Access Industries Holdings LLC has 55.91 million shares and ZACCARDELLI DAVID has 13.38 million shares.

Financial & Profitability Overview

Over the trailing twelve months, Verona Pharma has not generated any revenue. Returns are negative, with ROA at -17.71% and ROE at -21.89%.
On valuation metrics, Verona Pharma trades at a P/E of -295.69, P/S of 444.67 and P/B of 32.90. The current ratio is 10.71 and quick ratio is 10.54. Operationally, the company’s inventory turnover is 0.90 and cash conversion cycle is 438.57 days. Debt-to-equity is 0.88, supported by a cash flow-to-debt ratio of -0.04.

Quarterly Financial Highlights

For the quarter ended Dec 31, 2023, Verona Pharma posted revenue of $0.00, down slightly from $458.00K in the prior quarter. Gross profit was - $679.62K (margin 0.00%). Operating income was - $67.83M (margin 0.0%). Net income was- $54.58M (EPS - $0.69).
The company ended the quarter with $271.77M in cash and short-term investments, a total debt of $51.33M, and net debt of - $220.44M. Total assets were $308.12M, with equity of $249.28M. Financials further reflected weakness, with operating cash flow of - $50.42M, free cash flow of - $50.42M, and capital expenditures of $0.00.

Price Forecast & Outlook

Our AI price prediction model suggests that Verona Pharma plc stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 0.28%, with price expected at $107.21 by October 20, 2025, within a range of $103.22 to $111.17 3-Month Outlook: Projected rise of 0.94%, reaching $107.91 by January 02, 2026, with a range of $104.91 to $110.91. 1-Year Outlook: Projected gain of 29.36%, with price at $138.30 by October 06, 2026, within a range of $132.68 to $144.52.

Key Takeaways

Verona Pharma plc (NASDAQ:VRNA) shares are up 130.21% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows Verona Pharma plc trading at a premium to the broader market with a P/E of -295.69. Analyst sentiment is bullish, with the majority of ratings in Overweight territory and a mean price target of $55.40, suggesting -48.18% downside. Our AI forecast model points to short-term strength (0.28% over two weeks), a medium-term rise (0.94% over three months), and a longer-term gain (29.36% over one year), with expected trading ranges indicating moderate volatility.

Frequently Asked Questions

What is the current Verona Pharma plc (VRNA) stock price?

Verona Pharma plc (NASDAQ: VRNA) stock price is $106.91 in the last trading session. During the trading session, VRNA stock reached the peak price of $106.91 while $106.91 was the lowest point it dropped to. The percentage change in VRNA stock occurred in the recent session was 0.11% while the dollar amount for the price change in VRNA stock was $0.12.

VRNA's industry and sector of operation?

The NASDAQ listed VRNA is part of Biotechnology industry that operates in the broader Healthcare sector. Verona Pharma plc designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.

Who are the executives of VRNA?

Ms. Ostra Jewell
Senior Vice President of HR
Dr. Kathleen A. Rickard
Chief Medical Officer
Dr. David S. Zaccardelli
Pres, Chief Executive Officer & Executive Director
Dr. Tara Rheault M.P.H., Ph.D.
Senior Vice President of R&D
Dr. Peter Spargo
Senior Vice President of Chemistry Manufacturing & Controls
Ms. Nina Church
Executive Director of Global Clinical Devel.
Ms. Victoria Stewart
Director of Communications
Mr. Matthew Casbon
Vice President of Sales, Marketing & Training
Mr. Mark W. Hahn
Chief Financial Officer
Ms. Claire Louise Poll L.C.S.W., B.A., B Juris, LLB, ASIA
Gen. Counsel

How VRNA did perform over past 52-week?

VRNA's closing price is 243.87% higher than its 52-week low of $31.09 where as its distance from 52-week high of $106.93 is -0.02%.

How many employees does VRNA have?

Number of VRNA employees currently stands at 209.

Link for VRNA official website?

Official Website of VRNA is: https://www.veronapharma.com

How do I contact VRNA?

VRNA could be contacted at phone 442 032 834200 and can also be accessed through its website. VRNA operates from 3 More London Riverside, London, SE1 2RE, United Kingdom.

How many shares of VRNA are traded daily?

VRNA stock volume for the day was 1.87M shares. The average number of VRNA shares traded daily for last 3 months was 3.56M.

What is the market cap of VRNA currently?

The market value of VRNA currently stands at $72.68B with its latest stock price at $106.91 and 679.83M of its shares outstanding.

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

Employees	209
Beta	0.05
Sales or Revenue	$0.00
5Y Sales Change%	-1%
Fiscal Year Ends	December
Sector	Healthcare
Industry	Biotechnology

VRNA Company Profile and Key Details

Verona Pharma

Price Chart

Stock Price Today

Stock Snapshot

Relevant Articles

SEC Fillings

Current Report (8-k)

Annual Report (10-k)

Stock Price History Chart

Contact Details

About Company

Company Information

Stock Peers

Company Overview

Technical Performance

Valuation Metrics

Dividend & Fair Value

Earnings & Analyst Outlook

Shareholding & Insider Activity

Financial & Profitability Overview

Quarterly Financial Highlights

Price Forecast & Outlook

Key Takeaways

Frequently Asked Questions

Company Overview

Technical Performance

Dividend & Fair Value

Earnings & Analyst Outlook

Financial & Profitability Overview

Quarterly Financial Highlights

Shareholding & Insider Activity

Valuation Metrics

Key Takeaways

Price Forecast & Outlook